Instructional Leadership, emphasis: K-12 School Leadership (MEd)
Molecular structure and liquids used in research labs
  1. NAU
  2. Research
  3. Innovations
  4. Available technologies
  5. Biomedical innovations
  6. Compositions and Methods Using Antibody-Redirecting Peptides for Treatment of Disease

Compositions and Methods Using Antibody-Redirecting Peptides for Treatment of Disease

Description

This method harnesses pre-existing antibodies to rhinoviruses to neutralize the SARS-CoV-2 virus. Using a virome-wide screen, the inventors have identified a conserved linear peptide from the rhinovirus (Rv) capsid protein, which is recognized by high-affinity pre-existing antibodies in >99 percent of the general population. Based on this observation, the inventors have developed fusion peptides that are predicted to simultaneously bind SARS-CoV-2 and recruit pre-existing anti-Rv antibodies to form a presumptive immune complex that could redirect immunity against SARS-CoV-2 and reduce the severity of respiratory illness.

Additional information

Patent number and inventor

Patent pending

Jason Ladner, John Altin, and Sunil Sharma.

Potential applications

Clinical applications for SARS-CoV-2.

Benefits and advantages

The fusion peptide strategy provides a mechanism to engage the Fc-mediated effector functions of a monoclonal antibody (mAb) while avoiding the manufacturing challenges associated with mAb production.

Case number and licensing status

2020-042

This invention is available for licensing.